The Life Sciences M&A and MedTech team advised ophthalmic medical device company LumiThera on its acquisition by Alcon, the global leader in eye care dedicated to helping people see brilliantly. The acquisition includes the noninvasive Valeda® photobiomodulation (PBM) device for the treatment of early and intermediate dry age-related macular degeneration (AMD), and a sub-set of late dry AMD (non-central involving geographic atrophy). The acquisition does not include LumiThera's AdaptDX and Nova/Diopsys diagnostic devices, which were separated and spun-off to LumiThera’s shareholders, through the establishment of OpZira™, in a related spin-off transaction also advised by the Life Sciences team.
LumiThera, Inc. is an ophthalmic medical device company that is Harnessing the Power of Light™ to offer a comprehensive approach for detecting, treating, and monitoring retinal diseases, specifically dry AMD. LumiThera is the leader in ophthalmic PBM innovation.
OpZira, Inc. is a forward-thinking ophthalmic medical device company founded on a legacy of research excellence. The company delivers innovative technologies designed to enhance the detection and monitoring of ocular disease.
The Goodwin team was led by Mayan Katz, Amine Assouad, Beni Surpin and Daniela Sanchez, and included Xiaowei Wu and Grace Kim, Heath Ingram, Julie Tibbets, Marty Gomez, Kenneth Radcliffe, Janet Andolina, Benjamin Gossels, Arman Oruc, Eram Khan, Ortal Ben Aharon, Arom Yun, Natascha George, Zoe Li, Tim Holahan, Nina Ngo, Lauren NuDelman, Sebastian Walczak, Tobias Schulz, Matthew Cote, Scott Zilora, Allison Goldsher, Annie Kubanoff and Kerri Finn.
For more information on the deal, please read the signing press release, closing press release, and spin-off launch press release.